Clinical Trial Update: Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/2 study of a personalized tumor neoantigen mRNA therapy used as adjuvant treatment after pancreatic cancer resection.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Personalized tumor neoantigen mRNA therapy

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Cancer Resectable | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING